E M Terveer1, Y H van Beurden2, A Goorhuis3, J F M L Seegers3, M P Bauer4, E van Nood5, M G W Dijkgraaf6, C J J Mulder7, C M J E Vandenbroucke-Grauls8, H W Verspaget9, J J Keller10, E J Kuijper11. 1. Dept. of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: e.m.terveer@lumc.nl. 2. Dept. of Medical Microbiology & Infection Control, VU University Medical Center, Amsterdam, The Netherlands; Dept. of Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands. 3. Dept. of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands. 4. Dept. of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands. 5. Dept. of Internal Medicine, Havenziekenhuis, Rotterdam, The Netherlands. 6. Clinical Research Unit, Academic Medical Center, Amsterdam, The Netherlands. 7. Dept. of Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands. 8. Dept. of Medical Microbiology & Infection Control, VU University Medical Center, Amsterdam, The Netherlands. 9. Dept. of Biobanking and Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands. 10. Dept. of Gastroenterology, MC Haaglanden, The Hague, The Netherlands; Dept. of Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: j.keller@haaglandenmc.nl. 11. Dept. of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
BACKGROUND: Since 2013, several stool banks have been developed following publications reporting on clinical success of 'faecal microbiota transplantation' (FMT) for recurrent Clostridium difficile infections (CDI). However, protocols for donor screening, faecal suspension preparation, and transfer of the faecal suspension differ between countries and institutions. Moreover, no European consensus exists regarding the legislative aspects of the faecal suspension product. Internationally standardized recommendations about the above mentioned aspects have not yet been established. OBJECTIVE: In 2015, the Netherlands Donor Feces Bank (NDFB) was founded with the primary aim of providing a standardized product for the treatment of patients with recurrent CDI in the Netherlands. Standard operation procedures for donor recruitment, donor selection, donor screening, and production, storage, and distribution of frozen faecal suspensions for FMT were formulated. RESULTS AND DISCUSSION: Our experience summarized in this review addresses current donor recruitment and screening, preparation of the faecal suspension, transfer of the faecal microbiota suspension, and the experiences and follow-up of the patients treated with donor faeces from the NDFB.
BACKGROUND: Since 2013, several stool banks have been developed following publications reporting on clinical success of 'faecal microbiota transplantation' (FMT) for recurrent Clostridium difficile infections (CDI). However, protocols for donor screening, faecal suspension preparation, and transfer of the faecal suspension differ between countries and institutions. Moreover, no European consensus exists regarding the legislative aspects of the faecal suspension product. Internationally standardized recommendations about the above mentioned aspects have not yet been established. OBJECTIVE: In 2015, the Netherlands Donor Feces Bank (NDFB) was founded with the primary aim of providing a standardized product for the treatment of patients with recurrent CDI in the Netherlands. Standard operation procedures for donor recruitment, donor selection, donor screening, and production, storage, and distribution of frozen faecal suspensions for FMT were formulated. RESULTS AND DISCUSSION: Our experience summarized in this review addresses current donor recruitment and screening, preparation of the faecal suspension, transfer of the faecal microbiota suspension, and the experiences and follow-up of the patients treated with donor faeces from the NDFB.
Authors: Josbert J Keller; Maria Jgt Vehreschild; Christian L Hvas; Simon Md Jørgensen; Jouzas Kupciskas; Alexander Link; Chris Jj Mulder; Simon D Goldenberg; Ramesh Arasaradnam; Harry Sokol; Antonio Gasbarrini; Christoph Hoegenauer; Elizabeth M Terveer; Ed J Kuijper; Perttu Arkkila Journal: United European Gastroenterol J Date: 2019-11-14 Impact factor: 4.623
Authors: Tue Anker Mikkelsen; James Roger McIlroy; Madeleine Mimiague; Alice Rouanet; Luc Sterkman Journal: United European Gastroenterol J Date: 2020-02-23 Impact factor: 4.623
Authors: Mèlanie V Bénard; Clara M A de Bruijn; Aline C Fenneman; Koen Wortelboer; Judith Zeevenhoven; Bente Rethans; Hilde J Herrema; Tom van Gool; Max Nieuwdorp; Marc A Benninga; Cyriel Y Ponsioen Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752
Authors: Gianluca Ianiro; Marcello Maida; Johan Burisch; Claudia Simonelli; Georgina Hold; Marco Ventimiglia; Antonio Gasbarrini; Giovanni Cammarota Journal: United European Gastroenterol J Date: 2018-06-03 Impact factor: 4.623